Published Research Gastric Cytoprotection Sikiric et al
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
Discover Book Now GLP-1 is a once weekly injection that is FDA-approved to assist in weight management
Ensuring medication stability through proper refrigeration preserves the intended bioavailability for these precision approaches
Nasal administration, on the other hand, works through a completely different mechanism
BPC-157 works at a cellular level to jumpstart recovery by increasing fibroblast migration, inducing F-actin formation, and enhancing vascular expression (VEGFR2) for healthy blood vessel modulation